CJC-1295 No DAC is a synthetic research peptide derived from growth hormone-releasing hormone (GHRH) and designed to interact with GHRH receptors involved in growth hormone signaling. Unlike the DAC-modified form of CJC-1295, the No DAC version does not contain a Drug Affinity Complex, giving it a shorter duration of activity and making it useful in laboratory research examining more transient peptide signaling and receptor response.

CJC-1295 No DAC research has focused on its relationship with the growth hormone axis and the biological mechanisms involved in growth hormone secretion. Researchers have investigated its interaction with GHRH receptors in studies examining pituitary signaling, pulsatile growth hormone release, and downstream pathways associated with insulin-like growth factor-1 (IGF-1).

Another area of CJC-1295 No DAC research involves cellular and metabolic signaling. Laboratory studies have examined GHRH-related pathways in models involving protein synthesis, cellular activity, energy metabolism, and physiological responses associated with growth hormone and IGF-1 signaling.

The absence of DAC distinguishes this peptide from longer-acting CJC-1295 formulations and allows researchers to investigate GHRH receptor activity within shorter experimental timeframes. This characteristic makes CJC-1295 No DAC particularly relevant for controlled laboratory studies comparing peptide duration, receptor signaling, and growth hormone pathway activity.

CJC-1295 No DAC is synthetically produced and is typically supplied as a white, lyophilized powder in a 10mg format for controlled laboratory research.